{"id":532,"date":"2018-09-14T14:40:57","date_gmt":"2018-09-14T12:40:57","guid":{"rendered":"https:\/\/biologika-register.de?page_id=532"},"modified":"2018-09-14T14:40:57","modified_gmt":"2018-09-14T12:40:57","slug":"oral-abstract-presentations","status":"publish","type":"page","link":"https:\/\/biologika-register.de\/en\/rabbit\/results\/abstracts-and-posters\/oral-abstract-presentations\/","title":{"rendered":"Oral Abstract Presentations"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Title<\/b><\/td>\nMeeting, Location, Date<\/b><\/td>\n<\/tr>\n<\/thead>\n
What is the impact of poor prognostic factors on the achievement of low disease activity in patients with rheumatoid arthritis? Data from the German Biologics Register RABBIT and the early-arthritis cohort CAPEA <\/a><\/td>\n EULAR, Amsterdam,
13. \u2013 16. Juni 2018<\/td>\n<\/tr>\n
H\u00e4ufigkeit und Risikofaktoren inzidenter Psoriasis bei Patienten mit rheumatoider Arthritis unter biologischer und konventionell-synthetischer DMARD-Therapie <\/a><\/td>\n DGRh, Stuttgart,
6. \u2013 9. September 2017<\/td>\n<\/tr>\n
Wechsel von synthetischen auf biologische DMARDs \u2013 wird Methotrexat nicht ausreichend genutzt? <\/a><\/td>\n DGRh, Stuttgart,
6. \u2013 9. September 2017<\/td>\n<\/tr>\n
Bei rheumatoider Arthritis ist fr\u00fches Therapieansprechen auf konventionelle synthetische DMARDs ein besserer Pr\u00e4diktor f\u00fcr das Erreichen niedriger Krankheitsaktivit\u00e4t nach 12 und 24 Monaten als Autoantik\u00f6rper und Erosionen <\/a><\/td>\n DGRh, Stuttgart,
6. \u2013 9. September 2017<\/td>\n<\/tr>\n
The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events<\/a><\/td>\nACR, Washington DC,
11.-16. November 2016<\/td>\n<\/tr>\n
Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic DMARDs<\/a><\/td>\nACR, San Francisco,
7.-11. November 2015<\/td>\n<\/tr>\n
The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection<\/a><\/td>\nACR, San Francisco,
7.-11. November 2015<\/td>\n<\/tr>\n
Unbekannter Impfstatus: Pr\u00e4diktor f\u00fcr erh\u00f6htes Risikos schwerwiegender Infektionen?<\/a><\/td>\nDGRh, Bremen,
2.-5. September 2015<\/td>\n<\/tr>\n
Der Einfluss der Biologikatherapie auf das Risiko von Sepsis und Mortalit\u00e4t nach schwerwiegenden Infektionen<\/a><\/td>\nDGRh, Bremen,
2.-5. September 2015<\/td>\n<\/tr>\n
Schwangerschaftsverlauf bei Patientinnen mit rheumatoider Arthritis: Behandlungsentscheidungen, Krankheitsaktivit\u00e4t und Ausgang der Schwangerschaft<\/a><\/td>\nDGRh, Bremen,
2.-5. September 2015<\/td>\n<\/tr>\n
Discontinuation of biologic DMARDs increases the risk of sepsis and mortality after serious infection<\/a><\/td>\nEULAR, Rom,
10.-13. Juni 2015<\/td>\n<\/tr>\n
Pregnancies in patients with rheumatoid arthritis: Treatment decisions, course of the disease, and pregnancy outcomes<\/a><\/td>\nEULAR, Rom,
10.-13. Juni 2015<\/td>\n<\/tr>\n
Rezidivrisiko von Patienten mit Tumoranamnese unter verschiedenen Biologikatherapien<\/a><\/td>\nDGRh, D\u00fcsseldorf,
17.-20. September 2014<\/td>\n<\/tr>\n
Risikofaktoren f\u00fcr Schlaganfall bei Patienten mit rheumatoider Arthritis<\/a><\/td>\nDGRh, D\u00fcsseldorf,
17.-20. September 2014<\/td>\n<\/tr>\n
Effektivit\u00e4t eines ersten, zweiten oder dritten Biologikums in der Therapie der RA \u2013 Krankheitscharakteristika haben eine gr\u00f6\u00dfere Bedeutung als die Wahl der Substanz<\/a><\/td>\nDGRh, D\u00fcsseldorf,
17.-20. September 2014<\/td>\n<\/tr>\n
Arzneimittelsicherheit in der internistischen Rheumatologie – welche Informationen liefert das RABBIT-Register<\/a><\/td>\nDGRh, D\u00fcsseldorf,
17.-20. September 2014<\/td>\n<\/tr>\n
High risk of developing fatal infections in RA patients with congestive heart failure<\/a><\/td>\nEULAR, Paris,
11.-14. Juni 2014<\/td>\n<\/tr>\n
Risk of Cancer Recurrence or new tumors in RA Patients with Prior Malignancies treated with various Biologic Agents<\/a><\/td>\nACR, San Diego,
25.-30. Oktober 2013<\/td>\n<\/tr>\n
Patienten mit unzureichend kontrollierter rheumatoider Arthritis tragen ein erh\u00f6htes Risiko f\u00fcr akuten Myokardinfarkt<\/a><\/td>\nDGRh, Mannheim,
18.-21. September 2013<\/td>\n<\/tr>\n
Therapie der Rheumatoiden Arthritis im letzten Jahrzehnt – was hat sich ver\u00e4ndert?<\/a><\/td>\nDGRh, Mannheim,
18.-21. September 2013<\/td>\n<\/tr>\n
Acute myocardial infarction is driven by chronic systemic inflammation, irrespective of the kind of treatment – data from the German biologics register RABBIT<\/a><\/td>\nEULAR, Madrid,
12.-15. Juni 2013<\/td>\n<\/tr>\n
Krebs und Infektionen – Was ist der aktuelle Stand nach den Daten der europ\u00e4ischen Register?<\/a><\/td>\nDGRh, Bochum,
19.-22. September 2012<\/td>\n<\/tr>\n
Einfluss von Biologika auf die Verbesserung von M\u00fcdigkeit und Ersch\u00f6pfung (Fatigue)<\/a><\/td>\nDGRh, Bochum,
19.-22. September 2012<\/td>\n<\/tr>\n
Successful control of disease activity and treatment with biologics increase the life expectancy in rheumatoid arthritis patients<\/a><\/td>\nEULAR, Berlin,
6.-9. Juni 2012<\/td>\n<\/tr>\n
Validation of the RABBIT risk score for serious infections<\/a><\/td>\nEULAR, Berlin,
6.-9. Juni 2012<\/td>\n<\/tr>\n
Decreasing incidence of disability pensions in patients with rheumatoid arthritis in Germany<\/a><\/td>\nEULAR, Berlin,
6.-9. Juni 2012<\/td>\n<\/tr>\n
Unterschiede zwischen Mann und Frau bei rheumatoider Arthritis (RA)<\/a><\/td>\nDGRh, M\u00fcnchen,
31. August –
3. September 2011<\/td>\n<\/tr>\n
RA-Patienten, die eine Remission nach den neuen EULAR\/ACR-Kriterien erreichen, haben eine der Normalbev\u00f6lkerung vergleichbare Funktionsf\u00e4higkeit<\/a><\/td>\nDGRh, M\u00fcnchen,
31. August –
3. September 2011<\/td>\n<\/tr>\n
Interpreting safety data from registries<\/a><\/td>\nEULAR, London,
25.-28. Mai 2011<\/td>\n<\/tr>\n
Wie sicher ist die Biologika-Therapie im Alter? Ergebnisse aus RABBIT<\/a><\/td>\nDGRh, Hamburg,
15.-18. September 2010<\/td>\n<\/tr>\n
Risiken unter Biologikatherapie.<\/a><\/td>\nDGRh, Hamburg,
15.-18. September 2010<\/td>\n<\/tr>\n
Risikofaktoren f\u00fcr Sepsis unter anti-TNF Therapie<\/a><\/td>\nDGRh, Hamburg,
15.-18. September 2010<\/td>\n<\/tr>\n
Increased risk of sepsis after termination of anti-TNFa treatment<\/a><\/td>\nEULAR, Rom,
16.-19. Juni 2010<\/td>\n<\/tr>\n
Does the risk of serious infections in anti-TNF treated patients decrease over time?<\/a><\/td>\nACR, Philadelphia,
17.-21. Oktober 2009<\/td>\n<\/tr>\n
Effectiveness of treatment with Rituximab depends on autoantibody status – results from 2 years of experience in the German biologics register RABBIT<\/a><\/td>\nACR, Philadelphia,
17.-21. Oktober 2009<\/td>\n<\/tr>\n
Infektionen unter Biologika – Wie hoch ist das Risiko?<\/a><\/td>\nDGRh, K\u00f6ln,
23.-26. September 2009<\/td>\n<\/tr>\n
Biologic treatment in elderly patients: specific safety concerns<\/a><\/td>\nEULAR, Kopenhagen,
10.-13. Juni 2009<\/td>\n<\/tr>\n
Leflunomide increases the risk for incident peripheral neuropathies in patients with RA. <\/a><\/td>\nACR, San Francisco,
24.-29. Oktober 2008<\/td>\n		 <\/td>\n<\/tr>\n
Pregnancy Outcome after Exposure to Biologics: Results from the German Biologics Register RABBIT<\/a><\/td>\nACR, Boston,
06.-11. November 2007<\/td>\n<\/tr>\n
Reaktivierungen latenter Herpesinfektionen bei RA-Patienten unter anti-TNF Therapie – Daten aus dem RABBIT-Register<\/a><\/td>\nDGRh, Hamburg,
19.-22. September 2007<\/td>\n<\/tr>\n
Reactivation of herpesviruses (HHV-1 and HHV-3) infections is increased in RA patients treated with adalimumab or infliximab<\/a><\/td>\nEULAR,Barcelona,
13.-16.Juni 2007<\/td>\n<\/tr>\n
A highly active disease, treatment with glucocorticoids or coxibs but not the treatment with tnf inhibitors were identified as risk factors for a cardiac failure in RA<\/a><\/td>\nACR, Washington DC, 10.- 15. November 2006 <\/td>\n<\/tr>\n
Patients who are ineligible for clinical trials have lower treatment response in daily practice than those who fulfil standard inclusion criteria<\/a><\/td>\nACR, Washington DC, 10.- 15. November 2006 <\/td>\n<\/tr>\n
Erh\u00f6hen Biologika das Risiko einer Herzinsuffizienz bei RA-Patienten?<\/a> <\/td>\nDGRh, Wiesbaden,
18.-21. Oktober 2006<\/td>\n<\/tr>\n
Sicherheit und Vertr\u00e4glichkeit der Biologikatherapie – Neues aus dem RABBIT-Register<\/a><\/td>\nDGRh, Wiesbaden,
18.-21. Oktober 2006<\/td>\n<\/tr>\n
Patients treated with biologics in daily practice differ in treatment response according to their eligibility for the major RCTs<\/a><\/td>\nEULAR, Amsterdam,
21.-24. Juni 2006 <\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Title Meeting, Location, Date What is the impact of poor prognostic factors on the achievement of low disease activity in … mehr<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"parent":530,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_crdt_document":"","generate_page_header":"","footnotes":""},"class_list":{"0":"post-532","1":"page","2":"type-page","3":"status-publish","5":"infinite-scroll-item"},"_links":{"self":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/comments?post=532"}],"version-history":[{"count":2,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/532\/revisions"}],"predecessor-version":[{"id":1091,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/532\/revisions\/1091"}],"up":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/530"}],"wp:attachment":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/media?parent=532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}